NEW
YORK, Aug. 6, 2024 /PRNewswire/ -- The global
bispecific antibodies for cancer market size is estimated to
grow by USD 314.3 million from
2024-2028, according to Technavio. The market is estimated to grow
at a CAGR of 6.78% during the forecast period.
Increasing prevalence of cancer is driving market
growth, with a trend towards emerging bispecific antibody
generation platforms. However, high cost of drugs poses
a challenge. Key market players include ABL Bio Inc., AFFIMED N.V.,
Akeso Inc., Amgen Inc., Aptevo Therapeutics Inc., Astellas Pharma
Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly and Co., EPIMAB
BIOTHERAPEUTICS INC., F STAR THERAPEUTICS INC., F. Hoffmann La
Roche Ltd., Glenmark Pharmaceuticals Ltd., Johnson and Johnson
Services Inc., Mereo BioPharma Group Plc, Merus N.V., Pfizer Inc.,
Regeneron Pharmaceuticals Inc., TG Therapeutics Inc., Vadilal
Industries Ltd., and Y mAbs Therapeutics Inc..
![Technavio has announced its latest market research report titled Global bispecific antibodies for cancer market 2024-2028 Technavio has announced its latest market research report titled Global bispecific antibodies for cancer market 2024-2028](https://mma.prnewswire.com/media/2475332/Technavio_Global_bispecific_antibodies_for_cancer_market_2024_2028.jpg)
Get a detailed analysis on regions, market
segments, customer landscape, and companies - Click for the
snapshot of this report
Forecast
period
|
2024-2028
|
Base Year
|
2023
|
Historic
Data
|
2018 - 2022
|
Segment
Covered
|
Type (CD19 or CD3 and
CD30 or CD16A), Distribution Channel (Hospitals, Retail pharmacies,
and Online), and Geography (North America, Europe, Asia, and Rest
of World (ROW))
|
Region
Covered
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Key companies
profiled
|
ABL Bio Inc., AFFIMED
N.V., Akeso Inc., Amgen Inc., Aptevo Therapeutics Inc., Astellas
Pharma Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly and Co.,
EPIMAB BIOTHERAPEUTICS INC., F STAR THERAPEUTICS INC., F. Hoffmann
La Roche Ltd., Glenmark Pharmaceuticals Ltd., Johnson and Johnson
Services Inc., Mereo BioPharma Group Plc, Merus N.V., Pfizer Inc.,
Regeneron Pharmaceuticals Inc., TG Therapeutics Inc., Vadilal
Industries Ltd., and Y mAbs Therapeutics Inc.
|
Key Market Trends Fueling Growth
Bispecific antibodies are emerging as a promising cancer
treatment option due to their ability to target two distinct
antigens simultaneously. Companies like Aptech Therapeutics and
Xencor are collaborating with major pharmaceutical firms, such as
F. Hoffmann-La Roche and Amgen, to bring these innovative therapies
to market. Technologies like Amgen's BiTEs platform and
MicroGenics' DART platform have led to the development of
bispecific antibodies, such as RG7386 and RO7121661, using CrossMAb
technology. Xencor's XmAb antibody engineering platform alters the
fragment crystallizable domain to enhance immune regulation and
cytotoxic potency, resulting in stable, long-acting bispecific
antibodies like XmAb20717, XmAb22841, XmAb23104, XmAb24306, and
XmAb14045. Aptevo Therapeutics' ADAPTIR platform generates immune
therapeutics with unique mechanisms, including targeted cytokine
delivery and dual receptor targeting, as seen in APVO436 for acute
myeloid leukemia treatment. These platforms will fuel the growth of
the global bispecific antibodies for cancer market during the
forecast period.
The bispecific antibodies market is experiencing significant
growth, particularly in the cancer segment, due to the increasing
interest and confidence in personalized medicine. With strained
healthcare systems and a rising burden of chronic diseases such as
cancer, autoimmune disorders like rheumatoid arthritis, psoriasis,
and Crohn's disease, and mental health disorders, the need for
effective and targeted therapies is greater than ever.
Technological advancements in bispecific antibodies, such as those
targeting B-cell maturation antigen, are gaining regulatory
approval and making a mark in the treatment landscape. Notable
examples include Tibulizumab for lymphoma and Ozoralizumab for
multiple sclerosis. Collaborations between companies with
complementary expertise and technologies are driving developments
in this field. The regulatory environment for biologic therapies is
evolving, with precision medicine and targeted therapies gaining
traction. The bispecific antibodies market is expected to reach
USD8 trillion in healthcare
expenditure by 2030, making it a promising area for investment.
Despite these advancements, the bispecific antibodies market faces
challenges, including supply chain complexities and the diversion
of resources towards addressing infectious diseases and other
pressing healthcare needs. However, the potential benefits for
adult Americans battling cancer and other chronic diseases make
this an area worth pursuing.
Discover 360° analysis of this market. For
complete information, schedule your consultation- Book
Here!
Market Challenges
- The high cost of cancer drugs, including those used in the
treatment of non-small cell lung cancer with KEYTRUDA from
Merck, remains a significant challenge for patients in low- and
middle-income countries. With KEYTRUDA priced at USD107,520.00 (84,000
Euros) per patient, many cancer patients are unable to
complete their full course of therapy. Adherence to the full course
of therapy, including chemotherapy, targeted therapy, and
immunotherapy, is crucial for cancer treatment success. Currently,
only a few bispecific antibodies, such as BLINCYTO (blinatumomab),
Hemlibra (emicizumab), and Rybrevant (Amivantamab), are approved by
the US FDA for treating specific types of cancer. However, the high
cost of these drugs poses a significant challenge to their
widespread adoption, particularly in developed countries like the
US and Europe, where BLINCYTO
costs around USD89,000 per cycle and
is not covered by reimbursement schemes in most European countries.
In Japan, a single drip infusion
of BLINCYTO costs USD2,560
(JPY281,345). The high cost of these
drugs may hinder the growth of the global bispecific antibodies for
cancer market during the forecast period.
- The bispecific antibodies market is experiencing
significant growth due to the potential of these innovative
therapies in addressing various medical conditions, including
cancer and autoimmune disorders. However, strained healthcare
systems pose a challenge to the widespread adoption of these
treatments. Bispecific antibodies, such as Tibulizumab and
Ozoralizumab, offer precision medicine solutions for B-cell
maturation antigen-expressing cancers like lymphoma. However,
regulatory bodies require rigorous clinical trials to ensure safety
and efficacy. Technological advancements in bispecific antibody
production and collaborations between industry leaders like
Genentech and academic institutions bring complementary expertise
and technologies to the table. The regulatory environment for
biologic therapies is evolving, with increased interest and
confidence from stakeholders. The cancer segment of the bispecific
antibodies market is expected to dominate due to the high unmet
medical need. However, challenges in the supply chain and diverted
resources for chronic diseases like rheumatoid arthritis,
psoriasis, Crohn's disease, multiple sclerosis, mental health
disorders, and infectious diseases may impact market growth. With
healthcare expenditure projected to reach USD8 trillion by 2027, the bispecific antibodies
market holds immense potential.
For more insights on driver and
challenges - Download a Sample Report
Segment Overview
This bispecific antibodies for cancer market report extensively
covers market segmentation by
- Type
- 1.1 CD19 or CD3
- 1.2 CD30 or CD16A
- Distribution Channel
- 2.1 Hospitals
- 2.2 Retail pharmacies
- 2.3 Online
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 CD19 or CD3- The prevalence of acute
lymphoblastic leukemia (ALL), particularly in children,
adolescents, and young adults, is driving the demand for novel
treatments in the CD19 or CD3 segment of the bispecific antibodies
for cancer market. According to the National Cancer Institute, an
estimated 6,550 new cases and 1,330 deaths from ALL are expected in
the US in 2024. BLINCYTO, a CD19 or CD3 bispecific antibody, is
approved in 57 countries, including the US, EU, Canada, and Australia, for treating ALL. This drug,
designed in the BiTEs format, depletes B lymphocytes and
precursors, unlocking applications such as redirecting T-cells to
tumor cells, blocking two signaling pathways, and dual targeting of
disease mediators. Bispecific antibodies offer advantages over
monoclonal antibodies, including enhanced tumor killing, increased
binding specificity, and simultaneous blockage of multiple
pathways. The availability of reimbursement schemes and health
insurance coverage in the US further boosts market growth in the
CD19 or CD3 segment during the forecast period.
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data (2018 -
2022) - Download a Sample Report
Research Analysis
The bispecific antibodies market for cancer treatment is
experiencing significant growth due to the increasing demand for
targeted therapies. According to a recent report, the market is
projected to reach USD8 trillion by
2027. This growth can be attributed to the potential of bispecific
antibodies to address multiple targets in cancer cells, making them
more effective than traditional monoclonal antibodies. However, the
market faces challenges such as clinical trial complexities and
supply chain issues that can divert resources from research and
development. Bispecific antibodies are also being explored for the
treatment of mental health disorders, including anxiety and
depression. In cancer treatment, these antibodies are being used to
target multiple myeloma, and clinical trials are ongoing for
conditions such as psoriasis, Crohn's disease, and multiple
sclerosis. Technological advancements, such as the development of
novel manufacturing techniques and delivery systems, are expected
to drive further growth in the bispecific antibodies market.
Bispecific antibodies are a type of biologic therapy that can bind
to two different antigens, making them ideal for targeting cancer
cells with high specificity. They offer several advantages over
traditional chemotherapies and monoclonal antibodies, including
improved efficacy, reduced side effects, and the ability to
overcome resistance. However, the development of bispecific
antibodies is complex, requiring careful design and manufacturing
processes to ensure safety and efficacy. The adult American
population is a significant market for bispecific antibodies, with
a growing number of cases of cancer and other conditions that can
be treated with these therapies. Bispecific antibodies are being
developed for various types of cancer, including solid tumors and
hematological malignancies. Some of the promising candidates
include Tibulizumab and Ozoralizumab, which are currently in
clinical trials for various indications. Despite the potential of
bispecific antibodies, the market faces several challenges that can
impact their development and commercialization. One of the main
challenges is the complexity of clinical trials, which require
careful planning and execution to ensure safety and efficacy.
Another challenge is the supply chain, which can be disrupted by
various factors, including manufacturing issues and logistical
challenges. These challenges can lead to delays and increased
costs, making it essential for companies to have robust contingency
plans in place. In conclusion, the bispecific antibodies market for
cancer treatment is a promising area of growth, driven by the
potential of these therapies to address multiple targets in cancer
cells. However, the development of bispecific antibodies is
complex, and the market faces several challenges that can impact
their commercialization. Despite these challenges, technological
advancements and growing demand for targeted therapies are expected
to drive further growth in the bispecific antibodies market.
Market Research Overview
The bispecific antibodies market is poised for significant
growth due to the increasing burden of chronic diseases,
particularly cancer, which accounts for over 8 trillion dollars in healthcare expenditure in
Adult Americans alone. Bispecific antibodies, which can target
multiple antigens simultaneously, offer a promising solution for
various conditions, including cancer, autoimmune disorders, and
infectious diseases. The cancer segment is expected to dominate the
market, with multiple myeloma and lymphoma being key indications.
Clinical trials for bispecific antibodies against B-cell maturation
antigen and other targets are underway, driven by technological
advancements and regulatory bodies' increasing interest and
confidence. However, supply chain challenges and diverted resources
due to strained healthcare systems may pose obstacles to market
growth. Collaborations between companies with complementary
expertise and technologies are essential for overcoming these
challenges and bringing innovative bispecific antibodies to market.
In addition to cancer, bispecific antibodies are also being
explored for conditions such as rheumatoid arthritis, psoriasis,
Crohn's disease, and multiple sclerosis. Notable examples include
Tibulizumab and Ozoralizumab. The regulatory environment for
bispecific antibodies is evolving, with precision medicine and
personalized approaches gaining traction. Genentech is one of the
key players in the field, with a robust pipeline of bispecific
antibody candidates.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Type
-
- CD19 Or CD3
- CD30 Or CD16A
- Distribution Channel
-
- Hospitals
- Retail Pharmacies
- Online
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bispecific-antibodies-for-cancer-market-size-is-set-to-grow-by-usd-314-3-million-from-2024-2028--increasing-prevalence-of-cancer-to-boost-the-market-growth-technavio-302214289.html
SOURCE Technavio